Literature DB >> 10216202

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients.

A Garlind1, A Brauner, B Höjeberg, H Basun, M Schultzberg.   

Abstract

Evidence from epidemiological, clinical and experimental studies favour the hypothesis that inflammatory events are part of the neuropathology in Alzheimer's disease. Proinflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) have been found in activated microglia in the vicinity of amyloid plaques in Alzheimer's disease brain. In the present study, the levels of soluble IL-1 receptor type II (sIL-1R type II), IL-1 receptor antagonist (IL-1ra), IL-1beta, IL-6 and TNF-alpha were analyzed in cerebrospinal fluid (CSF) samples from Alzheimer's disease patients and control subjects. The levels of sIL-1R type II were significantly higher in CSF from Alzheimer's disease patients than in CSF samples from control subjects (38.5+/-8 pg/ml (mean+/-S.E.M.) vs. 7.9+/-4 pg/ml, p<0.05). Measurements of the proinflammatory cytokines IL-6 and TNF-alpha showed no significant difference between the two groups, and the levels of IL-1beta and IL-1ra in the present material were too low to permit detection. The increased levels of sIL-1R type II may reflect a compensatory mechanism to balance an increased release of IL-1 receptor agonists in the Alzheimer's disease brain. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216202     DOI: 10.1016/s0006-8993(99)01092-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  21 in total

Review 1.  Beta-secretase: structure, function, and evolution.

Authors:  Chitra Venugopal; Christina M Demos; K S Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

2.  α-Synuclein Aggregates with β-Amyloid or Tau in Human Red Blood Cells: Correlation with Antioxidant Capability and Physical Exercise in Human Healthy Subjects.

Authors:  Simona Daniele; Deborah Pietrobono; Jonathan Fusi; Caterina Iofrida; Lucia Chico; Lucia Petrozzi; Annalisa Lo Gerfo; Filippo Baldacci; Fabio Galetta; Gabriele Siciliano; Ubaldo Bonuccelli; Gino Santoro; Maria Letizia Trincavelli; Ferdinando Franzoni; Claudia Martini
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

Review 3.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

4.  Differential expression of matrix metalloproteinases 2 and 9 by glial Müller cells: response to soluble and extracellular matrix-bound tumor necrosis factor-alpha.

Authors:  G Astrid Limb; Julie T Daniels; Robert Pleass; David G Charteris; Philip J Luthert; Peng T Khaw
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients : an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay.

Authors:  Yuan Yuan Hu; Shan Shu He; Xiaochuan Wang; Qiu Hong Duan; Inge Grundke-Iqbal; Khalid Iqbal; Jianzhi Wang
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

Review 6.  Regulation of IL-1 signaling by the decoy receptor IL-1R2.

Authors:  Thomas Schlüter; Carsten Schelmbauer; Khalad Karram; Ilgiz A Mufazalov
Journal:  J Mol Med (Berl)       Date:  2018-08-15       Impact factor: 4.599

Review 7.  IL-1 receptor 2 (IL-1R2) and its role in immune regulation.

Authors:  Vanessa A Peters; Jennifer J Joesting; Gregory G Freund
Journal:  Brain Behav Immun       Date:  2012-11-27       Impact factor: 7.217

8.  The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease.

Authors:  S L Cole; R Vassar
Journal:  Curr Genomics       Date:  2007-12       Impact factor: 2.236

Review 9.  Heterogeneity of microglial activation in the innate immune response in the brain.

Authors:  Carol A Colton
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-05       Impact factor: 4.147

Review 10.  Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8.

Authors:  Martina Molgora; Domenico Supino; Alberto Mantovani; Cecilia Garlanda
Journal:  Immunol Rev       Date:  2018-01       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.